EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Pharmacologic Approach Against Glioblastoma—A Synergistic Combination of a Quinoxaline-Based and a PI3K/mTOR Dual Inhibitor

Vitória Santório de São José, Bruno Marques Vieira iD, Camila Saggioro de Figueiredo iD, Luis Gabriel Valdivieso Gelves iD, Vivaldo Moura Neto iD, Lídia Moreira Lima iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26136392 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Vitória Santório de São José und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-I…. Hauptthemen laut MEDLINE: Glioblastoma, Quinoxalines, TOR Serine-Threonine Kinases, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES), Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Conselho Nacional de Desenvolvimento Científico e Tecnológico—Brasil (CNPq).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GB) is the most common malignant primary CNS tumor with a fast-growing and invasive profile. As a result of the poor prognosis and limited therapy available, glioblastoma shows a high mortality rate. Given the scarcity of effective chemotherapy options, multiple studies have explored the potential of tyrosine kinase inhibitors. To mitigate resistance and improve potency and selectivity, we proposed the combination of a potent irreversible epidermal growth factor receptor inhibitor—LASSBio-1971—and a potent phosphatidylinositol-3-kinase/mammalian target of rapamycin dual inhibitor—Gedatolisib—through an in vitro phenotypic study using five human GB lines. Here, we aimed to establish the cytotoxic potency, selectivity, and effect on proliferation, apoptosis, migration, and the cell cycle. Our data showed the cytotoxic potency of Gedatolisib and LASSBio-1971 and improved selectivity in the GB cell lines. They highlighted the synergistic response from their combination and its impact on migration reduction, G0/G1 cell cycle arrest, GB cytotoxicity, and apoptosis-inducing effects for different GB cell lines. The drug combination studies in phenotypic in vitro models made it possible to suggest a new potential treatment for glioblastoma that justifies further safety in in vivo phases of preclinical trials with the combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaQuinoxalinesTOR Serine-Threonine KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsMTOR InhibitorsHumansCell Line, TumorDrug SynergismApoptosisCell ProliferationCell MovementBrain NeoplasmsMorpholinesTriazines

Stichwörter der Autor:innen

EGFRGedatolisibLASSBio-1971PI3KglioblastomamTORsynergistic effect

Substanzen

QuinoxalinesTOR Serine-Threonine KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsgedatolisibMTOR protein, humanMTOR InhibitorsMorpholinesTriazines

Autor:innen und Institutionen

  • Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-9…
  • Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
  • Laboratório de Biomedicina do Cérebro, Instituto Estadual do Cérebro Paulo Niemeyer (IECPN), Rio de Janeiro 20231-092, Brazil.
  • Laboratório de Medicina Experimental e Saúde, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, Brazil.
  • Laboratório de Neuropatologia, Instituto Estadual do Cérebro Paulo Niemeyer (IECPN), Rio de Janeiro 20231-092, Brazil.

ORCID-Profile: Bruno Marques Vieira, Camila Saggioro de Figueiredo, Luis Gabriel Valdivieso Gelves, Vivaldo Moura Neto, Lídia Moreira Lima

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico—Brasil (CNPq)

Zitieren

APA

de São José, V. S., Vieira, B. M., de Figueiredo, C. S., Valdivieso Gelves, L. G., Neto, V. M., & Lima, L. M. (2025). A Pharmacologic Approach Against Glioblastoma—A Synergistic Combination of a Quinoxaline-Based and a PI3K/mTOR Dual Inhibitor. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136392

Vancouver

de São José VS, Vieira BM, de Figueiredo CS, Valdivieso Gelves LG, Neto VM, Lima LM. A Pharmacologic Approach Against Glioblastoma—A Synergistic Combination of a Quinoxaline-Based and a PI3K/mTOR Dual Inhibitor. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136392

BibTeX
@article{deSoJos2025,
  author = {de São José, Vitória Santório and Vieira, Bruno Marques and de Figueiredo, Camila Saggioro and Valdivieso Gelves, Luis Gabriel and Neto, Vivaldo Moura and Lima, Lídia Moreira},
  title = {A Pharmacologic Approach Against Glioblastoma—A Synergistic Combination of a Quinoxaline-Based and a PI3K/mTOR Dual Inhibitor},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26136392}
}
Kostenlos starten →